Evidence map›Paper›PMID 39460812›Full record

ArticleClinical and experimental medicine2024

Influence of recipient KRAS gene rs712 polymorphisms on the overall survival rate of hepatocellular carcinoma after hepatic transplantation.

Tiancheng Chu, Rulin Zhang, Xiaolei Liu, Li Lin, Yanning Li, Ziguang Niu, Heng Quan, Yingying Zhao, Yaohua Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tiancheng Chu *Department of Laboratory Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China.
Rulin Zhang *Department of Laboratory Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China.
Xiaolei Liu *Department of Clinical Oncology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
Li LinDepartment of Laboratory Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China.
Yanning LiDepartment of Laboratory Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China.
Ziguang NiuDepartment of Clinical Oncology, the First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
Heng QuanSongjiang District Health Commission of Shanghai, Shanghai, China.
Yingying Zhao *Department of Laboratory Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China. 7879@126.com.
Yaohua Li *Department of Laboratory Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China. lyh20201107@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) recurrence appears commonly after liver transplantation (LT), and it severely affected the long-term survival of patients. Previous studies have proved that Rap1A is involved in hepatocarcinogenesis and metastasis, and demonstrated the significant association between KRAS rs712 polymorphism and HCC. However, the relationship between KRAS rs712 polymorphism and HCC recurrence after LT remained unclear. A total of 93 HCC patients who underwent LT from March 2008 to Dec 2015 was analyzed. The genotypes of both donors and recipients had been confirmed as KRAS rs712. The independent risk factors that associated with HCC recurrence were investigated with univariate and multivariate logistic regression analysis. The recurrence-free (RFS) and overall survival (OS) were calculated with Cox regression analysis. The KRAS rs712 genotype frequencies were determined using the Χ

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsLiver TransplantationPolymorphism, Single NucleotideProto-Oncogene Proteins p21(ras)AdultAgedFemaleGene FrequencyGenotypeHumansMaleMiddle AgedNeoplasm Recurrence, LocalRisk FactorsSurvival AnalysisKRAS protein, humanProto-Oncogene Proteins p21(ras)Hepatocellular carcinomaKRAS polymorphismPredictive markerRecurrence

Identifiers

PMID39460812
PMCPMC11512907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.